Emerging research suggest Retatrutide , a dual activator targeting both incretin and glucose-dependent insulinotropic polypeptide , appears to offer a promising step forward for weight loss . Initial human tests have indicated impressive reductions in abdominal tissue, possibly surpassing existing weight-loss medications . However , more evaluation